TABLE OF CONTENTS
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET 33
1.4 LIMITATIONS 35
1.5 MARKETS COVERED 35
2 MARKET SEGMENTATION 37
2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 CURRENCY AND PRICING 39
2.5 DBMR TRIPOD DATA VALIDATION MODEL 40
2.6 MULTIVARIATE MODELLING 43
2.7 TREATMENT TYPE LIFELINE CURVE 43
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.9 DBMR MARKET POSITION GRID 45
2.10 MARKET END USER COVERAGE GRID 46
2.11 VENDOR SHARE ANALYSIS 47
2.12 SECONDARY SOURCES 48
2.13 ASSUMPTIONS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 51
4.1 PORTER'S 5 FORCES 52
4.2 PESTEL ANALYSIS 53
5 EPIDEMIOLOGY 54
5.1 INCIDENCE OF ALL BY GENDER 54
5.2 TREATMENT RATE 54
5.3 MORTALITY RATE 54
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 55
5.5 PATIENT TREATMENT SUCCESS RATE 55
6 INDUSTRY INSIGHTS 56
6.1 PATENT ANALYSIS 56
6.2 DRUG TREATMENT RATE BY MATURED MARKETS 56
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 56
6.4 KEY PRICING STRATEGIES 57
6.5 KEY PATIENT ENROLLMENT STRATEGIES 58
7 MERGERS AND ACQUISITIONS 60
7.1 LICENSING: 60
7.2 COMMERCIALIZATION AGREEMENTS 60
8 PIPELINE ANALYSIS 61
8.1 PHASE 1 61
8.2 PHASE 2 61
8.3 PHASE 3 61
9 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS 62
9.1 FDA APPROVALS 62
9.2 EMA APPROVALS 63
10 MARKET OVERVIEW 64
10.1 DRIVERS 66
10.1.1 RISING PREVALENCE OF FIBROTIC DISEASES 66
10.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES 66
10.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES 67
10.2 RESTRAINTS 67
10.2.1 HIGH COST OF MEDICATION AND TREATMENTS 67
10.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES 67
10.3 OPPORTUNITIES 68
10.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 68
10.3.2 DEVELOPMENT OF NEW AND MORE EFFECTIVE THERAPIES FOR FIBROTIC DISEASES 68
10.4 CHALLENGES 69
10.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES. 69
10.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES, WHICH CAN RESULT IN SIGNIFICANT COSTS AND DELAYS IN DRUG DEVELOPMENT 69
11 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY TREATMENT 70
11.1 OVERVIEW 71
11.2 MEDICATION 73
11.2.1 INTEDANIB (OFEV) 74
11.2.2 PIRFENIDONE (ESBRIET) 74
11.3 ORGAN TRANSPLANTATION 74
11.4 OXYGEN THERAPY 75
11.5 OTHERS 76
12 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION 77
12.1 OVERVIEW 78
12.2 IDIOPATHIC PULMONARY FIBROSIS 81
12.3 HEPATIC CIRRHOSIS 81
12.4 RENAL FIBROSIS 82
12.5 CUTANEOUS FIBROSIS 83
12.6 OTHERS 84
13 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY END USER 85
13.1 OVERVIEW 86
13.2 HOSPITALS 89
13.3 SPECIALTY CLINICS 90
13.4 ACADEMIC AND RESEARCH INSTITUTES 90
13.5 OTHERS 91
14 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 92
14.1 OVERVIEW 93
14.2 HOSPITAL PHARMACY 96
14.3 RETAIL PHARMACY 96
14.4 OTHERS 97
15 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY REGION 98
15.1 MIDDLE EAST AND AFRICA 99
15.1.1 SOUTH AFRICA 105
15.1.2 SAUDI ARABIA 107
15.1.3 U.A.E 109
15.1.4 EGYPT 111
15.1.5 KUWAIT 113
15.1.6 ISRAEL 115
15.1.7 BAHRAIN 117
15.1.8 REST OF MIDDLE EAST AND AFRICA 119
16 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 120
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 120
17 SWOT ANALYSIS 121
18 COMPANY PROFILE 122
18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 122
18.1.1 COMPANY SNAPSHOT 122
18.1.2 REVENUE ANALYSIS 122
18.1.3 COMPANY SHARE ANALYSIS 123
18.1.4 PRODUCT PORTFOLIO 123
18.1.5 RECENT DEVELOPMENTS 123
18.2 GENENTECH, INC. 124
18.2.1 COMPANY SNAPSHOT 124
18.2.2 COMPANY SHARE ANALYSIS 124
18.2.3 PRODUCT PORTFOLIO 125
18.2.4 RECENT DEVELOPMENTS 125
18.3 SANDOZ INTERNATIONAL GMBH 126
18.3.1 COMPANY SNAPSHOT 126
18.3.2 COMPANY SHARE ANALYSIS 126
18.3.3 PRODUCT PORTFOLIO 127
18.3.4 RECENT DEVELOPMENTS 127
18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD. 128
18.4.1 COMPANY SNAPSHOT 128
18.4.2 REVENUE ANALYSIS 128
18.4.3 COMPANY SHARE ANALYSIS 129
18.4.4 PRODUCT PORTFOLIO 129
18.4.5 RECENT DEVELOPMENTS 129
18.5 ACCORD HEALTHCARE U.S. 130
18.5.1 COMPANY SNAPSHOT 130
18.5.2 COMPANY SHARE ANALYSIS 130
18.5.3 PRODUCT PORTFOLIO 131
18.5.4 RECENT DEVELOPMENTS 131
18.6 ABBVIE INC. 132
18.6.1 COMPANY SNAPSHOT 132
18.6.2 REVENUE ANALYSIS 132
18.6.3 PRODUCT PORTFOLIO 133
18.6.4 RECENT DEVELOPMENTS 133
18.7 ALPINE IMMUNE SCIENCES 134
18.7.1 COMPANY SNAPSHOT 134
18.7.2 REVENUE ANALYSIS 134
18.7.3 PRODUCT PORTFOLIO 135
18.7.4 RECENT DEVELOPMENTS 135
18.8 BELLBROOK LABS 136
18.8.1 COMPANY SNAPSHOT 136
18.8.2 PRODUCT PORTFOLIO 136
18.8.3 RECENT DEVELOPMENTS 136
18.9 BIOMX 137
18.9.1 COMPANY SNAPSHOT 137
18.9.2 REVENUE ANALYSIS 137
18.9.3 PRODUCT PORTFOLIO 138
18.9.4 RECENT DEVELOPMENTS 138
18.10 BRISTOL-MYERS SQUIBB COMPANY 139
18.10.1 COMPANY SNAPSHOT 139
18.10.2 REVENUE ANALYSIS 139
18.10.3 PRODUCT PORTFOLIO 140
18.10.4 RECENT DEVELOPMENTS 140
18.11 CAMBER PHARMACEUTICALS, INC. 141
18.11.1 COMPANY SNAPSHOT 141
18.11.2 PRODUCT PORTFOLIO 141
18.11.3 RECENT DEVELOPMENTS 141
18.12 ENVEDA 142
18.12.1 COMPANY SNAPSHOT 142
18.12.2 PRODUCT PORTFOLIO 142
18.12.3 RECENT DEVELOPMENTS 142
18.13 GILEAD SCIENCES, INC. 143
18.13.1 COMPANY SNAPSHOT 143
18.13.2 REVENUE ANALYSIS 143
18.13.3 PRODUCT PORTFOLIO 144
18.13.4 RECENT DEVELOPMENTS 144
18.14 INTERCEPT PHARMACEUTICALS, INC. 145
18.14.1 COMPANY SNAPSHOT 145
18.14.2 REVENUE ANALYSIS 145
18.14.3 PRODUCT PORTFOLIO 146
18.14.4 RECENT DEVELOPMENTS 146
18.15 KITHER BIOTECH S.R.L. 147
18.15.1 COMPANY SNAPSHOT 147
18.15.2 PRODUCT PORTFOLIO 147
18.15.3 RECENT DEVELOPMENTS 147
18.16 PHARMAXIS LTD 148
18.16.1 COMPANY SNAPSHOT 148
18.16.2 REVENUE ANALYSIS 148
18.16.3 PRODUCT PORTFOLIO 149
18.16.4 RECENT DEVELOPMENTS 149
18.17 REDX PHARMA PLC. 150
18.17.1 COMPANY SNAPSHOT 150
18.17.2 REVENUE ANALYSIS 150
18.17.3 PRODUCT PORTFOLIO 151
18.17.4 RECENT DEVELOPMENTS 151
18.18 VERONA PHARMA PLC 152
18.18.1 COMPANY SNAPSHOT 152
18.18.2 REVENUE ANALYSIS 152
18.18.3 PRODUCT PORTFOLIO 153
18.18.4 RECENT DEVELOPMENTS 153
19 QUESTIONNAIRE 154
20 RELATED REPORTS 157

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.